Sepsis may result due to an overwhelming life-threatening response to an infection. The B∙R∙A∙H∙M∙S Procalcitonin (PCT) assay aids in diagnosis of Sepsis and patient management to allow for timely antibiotic therapy, helping prevent serious medical complications.
For in vitro diagnostic use.
Around 50 million people develop sepsis each year leading to approximately 11 million deaths worldwide.1
Aggregate hospital costs for sepsis stays in the U.S reached $36.9 billion in both 2020 and 2021.2
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.3 Anyone affected by an infection can progress to sepsis conditions but some vulnerable populations such as elderly people, pregnant women, neonates, hospitalized patients, and people with HIV/AIDS, are at higher risk.4
In sepsis, organ dysfunction can be identified as an acute change in total SOFA (Sequential [Sepsis-related] Organ failure Assessment) score ≥ 2 reflect an overall mortality risk of approximately 10% in a general hospital population with suspected infection.3
It is a subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality. Patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain MAP (Mean Arterial Pressure ≥ 65mm Hg and having a serum lactate level ≥ 2mmol/L (18mg/dL) despite adequate volume resuscitation. With these criteria, hospital mortality is in excess of 40%.3
PCT is an inflammatory biomarker that is highly specific to bacterial infection and helps differentiate bacterial infection from other causes of inflammation such as that caused by viral infection. Additionally, it:
PCT is a more accurate diagnostic parameter for sepsis, a better predictor of mortality and a more reliable marker than other biomarkers, including C-reactive protein (CRP), Interleukins and Lactate levels.7
Recent studies suggest the value of PCT testing among COVID-19 patients as some patients may experience bacterial infections. This testing will help indicate who may benefit from antibiotics as part of their treatment.8
When making critical decisions, early diagnosis may help you select the best treatment for your patients.
Abbott's high-quality immunoassay menu helps laboratories meet requirements to be timely and precise with results.
Learn how Abbott has helped physicians evaluate suspected mild traumatic brain injury (mTBI).
Discover how Alinity uses powerful technology to help redefine and improve operational productivity and confidence in your laboratory.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
